Mersana Therapeutics Inc. (NASDAQ:MRSN) has announced updated provisional safety, efficacy, and tolerability results for the overlain cancer group from the continuing expansion part of the Phase 1 trial evaluating XMT-1536.
Mersana to present XMT-1536 study results at 2020 ESMO
XMT-1536 is the company’s first in class ADC candidate that targets NaPi2b whose results were presented at the 2020 Virtual European Society of Medical Oncology Congress. Lead investigator Erika Hamilton, a Breast Cancer and Gynaecology Cancer Research Program Director at Tennessee Oncology from Sarah Cannon Research, presented its executive team results.
Anna Protopapas, the CEPO and President of the company, said that the data supports the company’s ongoing development of XMT-1536, the first-in-class dolaflexin ADC that targets NaPi2b. Recently XMT-1536 received Fast Track Designation from the FDA. Anna added that they are committed to advancing XMT-1536 into registration trials based on its promising safety profile and observed antitumor activity on ovarian cancer patients with limited treatment alternatives and poor prognosis. The company is also looking forward to offering more mature and comprehensive results from the continuing expansion group by the end of 2020.
Phase 1 expansion study focused on previously treated ovarian cancer patients
The provision results analysis focused on the Phase 1 expansion study of the ovarian cancer group, which included heavily pre-treated individuals with refractory or platinum-resistant ovarian cancer, primary peritoneal, or fallopian tube cancer. The focus was patients who had previously received three therapy lines and even four lines irrespective of platinum status.
On August 18, 2020, the company released a data cutoff, including data from 47 patients. The data included additional follow-up data of 27 patients with ovarian cancer presented in May at the American Society of Clinical Oncology and 20 new patients who enrolled in the study between May 1, 2020, and August 18, 2002. Mersana reported a consistent safety profile with expansion data previously reported. The data also supports the NaPi2b patient selection strategy that depends on time, depth of study, and response quality.